Virtual Library
Start Your Search
O. Merimsky
Author of
-
+
P2.07 - Immunology and Immunotherapy (ID 708)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.07-026 - Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality (ID 8709)
09:30 - 16:00 | Author(s): O. Merimsky
- Abstract
Background:
Nivolumab, a human IgG4 programmed death (PD)-1 immune checkpoint inhibitor antibody, is approved in Israel and other parts of the world, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and disease progression during or after platinum-based chemotherapy, without a need to determine the level of PD-L1 expression in the tumor. In this series, we retrospectively analyzed the results of treating patients with NSCLC by nivolumab. This series represents real life results, out of a clinical trial, with broad inclusion criteria.
Method:
A retrospective analysis was carried out in a thoracic oncology service in a tertiary medical center (Tel-Aviv Medical Center), on patients with NSCLC, any subtype. All the patients were treated by nivolumab as part of a generous compassionate program supported by BMS.
Result:
The patients were allocated to one single arm of nivolumab 3mg/kg administered intravenously once every 2 weeks. Response assessment was performed in 63/77 patients who got at least four cycles of nivolumab. There was a complete response in 1 patient, partial response in 11, stable disease in 25, progressive disease (PD) in 25. The observed response rate of nivolumab as a service treatment in unselected patients with unknown PD-L1 status adenocarcinoma of the lung was 19 %. The disease control rate was 58.7%. Median progression free survival (PFS) from the first dose of nivolumab to treatment interruption is 4 months. Survival data were analyzed after 22 months. The overall survival was 34.9%, while PFS was 19.3%. All failures of nivolumab occurred within the first 12 months of administration. Median overall survival (OS) from the first dose of nivolumab till death or last follow up when alive, is 8 months.
Conclusion:
Anti PD1 agents are active and well tolerated in patients with NSCLC. This is based on selected population in clinical trials and on non-selected cohorts reflecting daily service in thoracic oncology units.
